Speed bumps on the road to antibody therapy.
Scheinberg
D A
DA
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D000069283:Rituximab; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C092612:BR96-doxorubicin immunoconjugate; D000069283:Rituximab; D004317:Doxorubicin